MLANA and melanoma: Current examples include polyfunctional CAR-T cells that may be a surrogate biomarker for treatment efficacy, with Melan-A recognised by T cell 1 (MART1)-specific TCR-engineered T cells revealing an association between TNFα and IFNγ secretion and melanoma patients with a delay in their time to disease-related relapse [14].